{"schema_version":"secwatch.filing_event.v1","accession":"0001384101-26-000002","form_type":"8-K","ticker":"VCYT","cik":"0001384101","company_name":"VERACYTE, INC.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.957864+00:00","generated_at":"2026-05-16T10:48:56.102274+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Veracyte prelim Q4 rev $138M-$140M (+16-18% YoY); guides FY26 rev $570M-$582M","bullets":["FY2025 total revenue $515M-$517M (+16% YoY); testing revenue $491M-$493M.","Decipher volume +27% to ~102K; Afirma volume +11% to ~67.7K in FY2025.","Prelim FY2025 adj EBITDA margin >25%; FY2026 margin guided at 25%.","FY2026 total revenue guidance 10-13% growth ($570M-$582M); testing rev +14-16% ($559M-$569M excl. new tests).","CEO cites upcoming US launch of Prosigna and TrueMRD as growth catalysts."],"urls":{"canonical":"https://secwatch.observer/filing/0001384101-26-000002","json":"https://secwatch.observer/filing/0001384101-26-000002.json","markdown":"https://secwatch.observer/filing/0001384101-26-000002.md","text":"https://secwatch.observer/filing/0001384101-26-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1384101/000138410126000002/0001384101-26-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1384101/000138410126000002/vcyt-20260111.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:48:56.102274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}